Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 by rgunnam

VIEWS: 6 PAGES: 2

More Info
									Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

The CF Therapeutics Market Shows High Growth Until 2018

GlobalData’s analysis suggests that the global Cystic Fibrosis (CF) therapeutics market valued at $622.9m
in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 12.0% to reach $1,096.3m in 2010.
GlobalData forecasts that the global CF therapeutics market will grow at a high CAGR of 10.7% over the
next eight years, to reach $2,472.8m by 2018. This growth is primarily attributed to an increase in the
annual cost of treatment due to the expected launch of novel, premium priced therapies VX-770 and
Ataluren during the forecast period. VX-770 is expected to be launched in late 2012 and Ataluren in
2014. An increase in the treatment seeking population due to an increase in the life expectancy and
increasing awareness leading to diagnosis at an early stage will drive the CF therapeutics market. The
current competition in the CF therapeutics market is weak, primarily dominated by TOBI (inhaled
tobramycin), Pulmozyme (dronase alpha), pancreatic enzyme and many other antibiotics such as
meropenem, ceftazidime and hypertonic saline solution, which provide only symptomatic treatment in
CF.

Novartis AG (Novartis) and F. Hoffmann–La Roche Ltd. (Roche) are the leading competitors in the global
CF therapeutics market. Together, these companies account for a major share in the global CF
therapeutics market. However, Cystic Fibrosis Foundation Therapeutics (CFFT) and companies such as
Gilead Sciences, Vertex Pharma, Pharmaxis and Pari Pharma, with some technologically advanced
products in their pipeline portfolios, are expected to attract the majority of investors’ attention in near
future.

Only four key products (TOBI, Pulmozyme, Cayston (aztreonam inhalation) and Creon (pancrelipase) are
approved for the treatment of CF. Cayston and Creon have been recently approved for the treatment of
CF, suggesting that current competition in the CF therapeutics market is weak. The future could see
more competition following multiple product launches by the leading and emerging manufacturers, who
are concentrating on novel therapies such as Cystic Fibrosis Transmembrane Conductance regulator
(CFTR), potentiator and corrector. It is a gene therapy which acts on specific G551D mutation and
nonsense mutation of CF. It functions as an ion channel across the cell membrane found in tissues that
produce mucus, sweat, saliva, tears and digestive enzymes. In addition to this, novel formulations, anti-
inflammatory agents, mucolytics and pancreatic enzyme therapies are being developed for the
treatment of CF.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Cystic-Fibrosis-Therapeutics-
Pipeline-Assessment-and-Market-Forecasts-to-
2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=dcsto

Industry analysis specialist, GlobalData, has released its new report, “Cystic Fibrosis (CF) Therapeutics
- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information
on the global Cystic Fibrosis therapeutics market, and provides analysis of a number of key areas. The
report identifies the key trends shaping and driving the global Cystic Fibrosis therapeutics market and
provides insights into the current competitive landscape and emerging companies expected to
significantly alter the market positioning of current market leaders. Most importantly, the report
provides valuable insights into the pipeline products within the global Cystic Fibrosis sector. This report
is built using data and information sourced from proprietary databases, primary and secondary research
and inhouse analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Cystic-Fibrosis-Therapeutics-Pipeline-
Assessment-and-Market-Forecasts-to-
2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=dcsto

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:                +44 207 753 4299
                       +44 1204 543 533
Asia Pacific:          +91 40 6616 6782

								
To top